Serial Changes in sTREM-1 During Ventilator-associated Pneumonia (VAP)

• Sponsor: Mackay Memorial Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT00976157
• Collaborator: (none)
• Enrollment: 35
• Location: 1
• Duration (Months): 25
• Patients Per Site Per Month: 1.4

Study Details

Study Description

Brief Summary

Triggering receptor expressed on myeloid cells (TREM)-1 is a recently described molecule that plays an important role in myeloid cell-activated inflammatory responses. The aim of this study was to investigate the evolutional change of soluble TREM-1 (sTREM-1) in bronchoalveolar lavage (BAL) fluid of clinically diagnosed ventilator-associated pneumonia (VAP) and its correlation with response to treatment and outcome.

Condition or Disease	Intervention/Treatment	Phase
Pneumonia	Procedure: Bronchoscopy BAL

Detailed Description

A prospective, interventional study conducted between August 2006 and August 2007 in MICU in Mackay Memorial Hospital, 35 patients with clinically diagnosed VAP were investigated. sTREM-1 was measured in BAL samples using ELISA at the onset, 4th - 5th and 7th - 9th day of clinical diagnosis of VAP.Of these 35 patients, 27 had positive BAL culture. The sTREM-1 levels in BAL fluid were measured and compared between patients with positive BAL culture and negative BAL culture. Serial changes in sTREM-1 levels were evaluated in relation to patient outcome.

Study Design

• Study Type: Observational
• Actual Enrollment: 35 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: Serial Changes of Soluble TREM-1 Level in Bronchoalveolar Lavage Fluid During Ventilator-associated Pneumonia
• Study Start Date: Aug 1, 2006
• Actual Primary Completion Date: Dec 1, 2007
• Actual Study Completion Date: Sep 1, 2008

Arms and Interventions

Arm

Intervention/Treatment

Ventilator-associated pneumonia

Procedure: Bronchoscopy BAL; The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.

Outcome Measures

Primary Outcome Measures

1. mortality [18 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 86 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• adult patients (older than 18 years)with clinically suspected VAP

Exclusion Criteria:

• mechanically ventilated patients post cardiopulmonary resuscitation

• patients with end stage diseases with life expectancy less than 3 months

• patients with solid or hematology transplantation

• patients on immunosuppressive agents

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mackay Memorial Hospital	Taipei		Taiwan	106

Sponsors and Collaborators

• Mackay Memorial Hospital

Investigators

• Principal Investigator: Chien Liang Wu, MD, Mackay Memorial Hospital, Taipei, Taiwan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00976157
• Other Study ID Numbers: MMH-I-S-201
• First Posted: Sep 14, 2009
• Last Update Posted: Sep 15, 2009
• Last Verified: Sep 1, 2009

• Keywords provided by , ,: STREM-1; BAL; VAP
• Additional relevant MeSH terms: Pneumonia; Pneumonia, Ventilator-Associated

Study Results

No Results Posted as of Sep 15, 2009